# ODYSSEY (PENTA 20)

> **NCT02259127** · PHASE2,PHASE3 · COMPLETED · sponsor: **PENTA Foundation** · enrollment: 792 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Dolutegravir
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT02259127
- **Lead sponsor:** PENTA Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-20
- **Primary completion:** 2021-03-02
- **Final completion:** 2023-12-07
- **Target enrollment:** 792 (ACTUAL)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259127, "ODYSSEY (PENTA 20)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02259127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*